Further studies addressing the mechanisms as to how the differential expression of IL7R-alpha chains translates into autoimmune inflammation in MS are underway and will be presented. .5% primary progressive -PP] in the nonactive phase of their illness were selected from the CHP's Clinical Immunology Unit and Neuroimmunology Outpatient Clinic.